Evidence map›Paper›PMID 28331043›Full record

ArticleThe European respiratory journal2017

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.

Dennis Falzon, Holger J Schünemann, Elizabeth Harausz, Licé González-Angulo, Christian Lienhardt, Ernesto Jaramillo, Karin Weyer

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The European respiratory journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 8 pooled it
35.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 8 syntheses or guidelines pooled it, 422 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. A systematic review on extensively drug-resistant tuberculosis from 2009 to 2020: special emphases on treatment outcomes.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023
    Pooled it
  5. Pooled it
  6. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2019
    Guideline
  7. Pooled it
  8. Pooled it
  9. Effect of HIV on bedaquiline and delamanid pharmacokinetics in patients with multidrug-resistant TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2025
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Dennis FalzonGlobal TB Programme, World Health Organization, Geneva, Switzerland falzond@who.int.
Holger J SchünemannMcMaster University Health Sciences Centre, Hamilton, ON, Canada.
Elizabeth HarauszUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Licé González-AnguloGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Christian LienhardtGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Ernesto JaramilloGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Karin WeyerGlobal TB Programme, World Health Organization, Geneva, Switzerland.
World Health Organization · CHMcMaster University Medical Centre · CAWalter Reed Army Institute of Research · US

Funding

World Health Organization 001
6 · The paper itself

Abstract

Antimicrobial resistance is a major global concern. Tuberculosis (TB) strains resistant to rifampicin and other TB medicines challenge patient survival and public health. The World Health Organization (WHO) has published treatment guidelines for drug-resistant TB since 1997 and last updated them in 2016 based on reviews of aggregated and individual patient data from published and unpublished studies. An international expert panel formulated recommendations following the GRADE approach. The new WHO guidelines recommend a standardised 9-12 months shorter treatment regimen as first choice in patients with multidrug- or rifampicin-resistant TB (MDR/RR-TB) strains not resistant to fluoroquinolones or second-line injectable agents; resistance to these two classes of core second-line medicines is rapidly detectable with molecular diagnostics also approved by WHO in 2016. The composition of longer regimens for patients ineligible for the shorter regimen was modified. A first-ever meta-analysis of individual paediatric patient data allowed treatment recommendations for childhood MDR/RR-TB to be made. Delamanid is now also recommended in patients aged 6-17 years. Partial lung resection is a recommended option in MDR/RR-TB care. The 2016 revision highlighted the continued shortage of high-quality evidence and implementation research, and reiterated the need for clinical trials and best-practice studies to improve MDR/RR-TB patient treatment outcomes and strengthen policy.

Indexed as

Antitubercular AgentsDisease ManagementDrug Administration ScheduleHumansMycobacterium tuberculosisPractice Guidelines as TopicRifampinTuberculosis, Multidrug-ResistantWorld Health OrganizationAntitubercular AgentsRifampin

Identifiers

PMID28331043
PMCPMC5399349
OpenAlexW2603888074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.